Gilead avoids $1.2bn patent clash at SCOTUS

10-01-2023

Muireann Bolger

Gilead avoids $1.2bn patent clash at SCOTUS

shutterstock_1569359980_Sundry Photography

Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.


Gilead, SCOTUS, Amgen, Sanofi, BMS, patent, cancer treatment

LSIPR